AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca PLC

AstraZeneca ( ($GB:AZN) ) has shared an update. AstraZeneca shareholders overwhelmingly approved all resolutions at the 9 April 2026 Annual General...

AstraZeneca Wins Strong Shareholder Backing at 2026 AGM

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. The ROSY-F roll-over study from AstraZeneca (AZN) aims to keep patie...

AstraZeneca Extends Fasenra’s Runway With New Long-Term Safety Study

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The ESPERANZA study, officially titled “External Control Arm Study for T-D...

ESPERANZA Update: Real-World Data Study Could Broaden AstraZeneca’s T-DXd Cancer Opportunity

J.P. Morgan analyst Richard Vosser maintained a Buy rating on AstraZeneca today and set a price target of £160.00. According to TipRanks, Vosser is...

J.P. Morgan Reaffirms Their Buy Rating on AstraZeneca (AZN)

In a report released yesterday, Rajan Sharma from Goldman Sachs maintained a Buy rating on AstraZeneca, with a price target of p16,600.00. The comp...

AstraZeneca (AZN) Receives a Buy from Goldman Sachs

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. AstraZeneca (~AZN) has updated a Phase I clinical trial called “A Phase I ...

AstraZeneca Completes Early Obesity Trial for AZD6234, Nudging Long-Term Growth Hopes

President Donald Trump on Thursday signed an executive order to impose a 100% tariff on imported branded medicines (patented drugs and their active...

AZN, NVO, NVS: What Does Trump’s New 100% Tariff Mean for Pharma Giants?

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca Tests Cancer Drug Mix for Safety and Drug Interactions T...

AstraZeneca’s New Cancer Combo Trial Signals Steady Progress in Antibody Drug Conjugates

Jefferies analyst Michael Leuchten maintained a Buy rating on AstraZeneca on March 27 and set a price target of p18,000.00. Leuchten covers the Hea...

AstraZeneca (AZN) Receives a Buy from Jefferies

Citi analyst Graham Parry maintained a Buy rating on AstraZeneca today and set a price target of £170.00. According to TipRanks, Parry is a 2-star ...

Citi Sticks to Its Buy Rating for AstraZeneca (AZN)

Traders can read the latest stock market happenings in our daily wrap-up.


Morning News Wrap-Up: 3/27/26: Today’s Biggest Stock Market Stories

J.P. Morgan analyst Richard Vosser maintained a Buy rating on AstraZeneca today and set a price target of £138.30. According to TipRanks, Vosser is...

J.P. Morgan Keeps Their Buy Rating on AstraZeneca (AZN)

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. The CHOICE study, formally titled “A Cross-sectional Survey-based St...

AstraZeneca’s CHOICE Survey Targets Real-World Drivers of EGFR-TKI Use in China

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The study, titled “Clinical Observational Study of Remote, Non-invasive, M...

AstraZeneca Completes Heart Failure Wearable Study, Boosting Its Digital Health Edge

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca’s new China study takes a close look at how different la...

AstraZeneca’s Pan-HER2 China Study Builds a Quiet Long-Term Edge in Oncology

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. The REVIVE study, formally titled “Biomarker-Directed Treatment in P...

AstraZeneca’s REVIVE Trial Targets Relapse After Osimertinib, Extending the Lung Cancer Playbook

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca Backs Real-World Kidney Study in China The study, titled...

AstraZeneca Expands Real-World Push With New China Kidney Registry

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. AstraZeneca’s EXACOS EG Population study, officially titled “Exacerbations...

AstraZeneca Halts Egyptian COPD Burden Study, Trimming Near-Term Data Upside

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. The study “A Study to Evaluate the Accuracy of Primary Care Diagnosi...

AstraZeneca Advances Primary Care Lung Diagnosis Study With Global Reach

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The study LYNPARZA Tablets 100mg, 150mg General Drug Use-results Study tra...

AstraZeneca’s Lynparza Safety Study in Japan: What the Latest Update Signals for AZN Investors

The wealth of the Tesla CEO dwarfs other billionaires. 


Elon Musk Is Close to Becoming the World’s First Trillionaire as His Net Worth Hits $839 Billion

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. The DURGA-4 study, formally titled “A Phase III Open-label, Randomis...

AstraZeneca’s DURGA-4 CAR-T Study Puts New Pressure on Multiple Myeloma Rivals

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca study tracks how two versions of its asthma drug move th...

AstraZeneca Advances Pediatric Symbicort Device Study, Supporting Long Term Respiratory Strategy

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The study Understanding Non-small Cell Lung Cancer Patient Characteristics...

AstraZeneca Wraps Real-World Lung Cancer Study, Sharpening Market Insight for AZN Investors

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The study “Specific Use-results Study of IMJUDO Intravenous Infusion 25 mg...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AZN	$204.27	0.00%	2.24M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AZN	$204.27	0%	2.24M
3
4
5
6

AZN

AZN

Get AstraZeneca PLC Data in Excel

Get AstraZeneca PLC Data in Excel